SMS PharmaceuticalsQ2 FY23

SMS Pharmaceuticals Q2 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹486.5P/E: 39.0Market Cap: ₹4.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

No

Order

N/A

Capex

No

0 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • FY '23 revenue growth target is around 10%; FY '24 projected growth is 15% to 20%.
  • Volume growth is expected to be strong, with sequential and year-over-year volume growth seen; e.g., 30%-35% volume growth reported despite price corrections.
  • Focus on ramping up ibuprofen capacity to reach INR 600-700 crores topline, becoming one of the largest manufacturers.
  • Efforts to fill existing large capacity (e.g., 2,000 KL in Vizag plant) with high volume products and some niche products.
  • New product launches and geographic expansion planned; anti-diabetic segment expected to contribute around 25%-30% of topline in future.
  • Growth driven by higher volumes, operating leverage, and process improvements to improve margins alongside revenue increase.
  • Inventory destocking expected to gradually ease over 2-3 quarters, aiding smoother sales growth.

See what SMS Pharmaceuticals management said on margin guidance — free account, 30 seconds.

Fundraise plans

No
  • No significant capital expenditure (capex) or expansion planned for the next one year, indicating no major immediate need for fundraising.
  • The company plans only small capex related to environmental initiatives (e.g., multi-effect evaporation operator).
  • Current focus is on consolidating and filling existing capacity rather than building new capacity.
  • Long-term debt is INR 170 crores and short-term debt is INR 90 crores, with an average borrowing cost below 8%.
  • No explicit mention of any ongoing or planned fundraising through debt or equity in the call transcript.
  • Emphasis is on growing revenue via existing capacities and product mix rather than through additional funding.

See what SMS Pharmaceuticals management said on order book — free account, 30 seconds.

Capex plans

No
  • No significant capex planned for the next one year as the company aims to consolidate its existing capacities.
  • Small capex planned is related to environmental upgrades, such as installing multi-effect evaporators (ME) and other environmental compliance equipment.
  • Focus is on utilizing existing capacity (about 2,000 KL at Vizag plant for Ibuprofen) by filling it with more products rather than expanding physical capacity.
  • Strategic focus is on product mix expansion, backward integration, and entering new markets rather than capital investment in new facilities.
  • No new building blocks or capacity additions are planned currently.

Track SMS Pharmaceuticals — get its next earnings analysis in your feed

How does SMS Pharmaceuticals rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisSMS Pharmaceuticals
Rev 3Mar 3

How does SMS Pharmaceuticals rank in Pharmaceuticals & Biotechnology?

Compare SMS Pharmaceuticals against every Pharmaceuticals & Biotechnology company (Q2 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →